Comparison · NCT00658632-sae
ESO 40 mg vs RAB ER 50 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ESO 40 mg vs RAB ER 50 mg: serious adverse events. Trial comparisons, record NCT00658632-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00658632-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00888 | 0.00407 | 0.0192 | wilson | |
| Risk in group 2 | 0.00438 | 0.00149 | 0.0128 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0045 | -0.00519 | 0.0152 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.03 | 0.509 | 8.07 | log | |
| Odds ratio, group 1 over group 2 | 2.04 | 0.507 | 8.17 | log | |
| Number needed to harm, for one more participant with a serious adverse event on ESO 40 mg than on RAB ER 50 mg | 222 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ESO 40 mg | ESO 40 mg capsule concurrently with placebo (identical in appearance to the RAB ER 50 mg capsule), once daily for 4 to 8 weeks. | 6 | 676 | EG000 |
| Group 2 | RAB ER 50 mg | RAB ER 50 mg capsule concurrently with placebo (identical in appearance to the ESO 40 mg capsule), once daily for 4 to 8 weeks. | 3 | 685 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
For each participant, from the time of administration of the first dose of study drug up to 30 days after the administration of the last dose of study drug or up to resolution of adverse event or up to approximately 10 weeks.
Source ClinicalTrials.gov
Trial
- Title
- Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
- NCT number
- NCT00658632
- Phases
- PHASE3
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Rabeprazole sodium, Esomeprazole
- Lead sponsor
- Eisai Inc.
- Results first posted
- 2015-06-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00658632?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00658632-sae